In addition, since the targeting of VEGF-VEGFR inhibition has significant therapeutic potential for anti-cancer, recent works have used small-molecule compounds such as tyrosine kinase inhibitors that inhibit VEGFR activation and downstream signaling to explore the structural basis for anti-angiogenic therapy35–37. Here, VEGFA is linked to cancer.